Web Design for Pharmaceutical Companies: A 2026 UK Guide

Pharma web design is the only branch of web design where the wrong sentence on a page can trigger a regulatory complaint. Everything else follows from that.

Why Pharma Web Design Is a Different Discipline

Most website projects optimise for one thing: getting the visitor to act. Pharmaceutical web design optimises for two things simultaneously, and they pull against each other. You need the site to communicate clearly and persuasively, and you need every claim on it to survive scrutiny from the Medicines and Healthcare products Regulatory Agency and, for most companies operating in the UK, from the industry's own code of practice.

That constraint reaches further into the build than people expect. It is not a compliance review bolted onto the end. It changes the information architecture (because patient and healthcare professional content must be separated), the content model (because every claim needs a traceable reference), the publishing workflow (because sign-off has to be recorded), and even the component library (because a testimonial carousel or a "results in 7 days" badge that is fine for a consumer brand may be unusable for you).

The commercial consequence is that pharmaceutical websites tend to be either badly over-lawyered, to the point of being useless to the people they are meant to serve, or dangerously casual, built by an agency that treated it as a normal corporate site. The good ones treat the regulatory boundary as a design input from day one, which is genuinely easier than retrofitting it, and considerably cheaper than a rebuild after a complaint is upheld.

Six Pillars of Effective Pharmaceutical Web Design

Build for the MHRA and the ABPI Code From the Start

UK medicines advertising is governed by the Human Medicines Regulations 2012 and, for member companies, by the ABPI Code of Practice administered by the PMCPA. The single rule that shapes site structure most is that prescription-only medicines cannot be advertised to the general public. Decide early which audiences each section serves, and build the access controls before you write the copy, not after.

Treat Accessibility as a Legal Baseline

Your users include people with impaired vision, tremor, cognitive fatigue, and low health literacy, often because of the conditions your products treat. Target WCAG 2.2 AA as a minimum: proper heading order, keyboard operability, 4.5:1 contrast, visible focus states, and forms that announce their errors. Accessibility overlays are not a substitute and are widely regarded as a liability rather than a fix.

Separate Patient and Healthcare Professional Journeys

HCP content requires a gate. An interstitial that asks the visitor to confirm they are a UK healthcare professional is the standard pattern, and it needs to be a genuine decision point rather than a dismissible banner. Keep the two content sets in separate site sections with distinct URL paths, so search engines, analytics, and your own reviewers can tell them apart at a glance.

Earn Trust With Transparency and Evidence

Every efficacy or safety claim needs a visible, dated reference. Publish author credentials, medical review dates, and the summary of product characteristics where relevant. This is a compliance requirement, but it is also the single biggest driver of perceived credibility for prescribers and journalists, both of whom check.

Protect Data and Lock Down Security

Adverse event forms, patient support sign-ups, and HCP registrations collect special category data under UK GDPR. That means a lawful basis, a data protection impact assessment, encryption in transit and at rest, minimal retention, and a hosting arrangement you can actually evidence. Assume you will be asked to prove all of it.

Structure Content for Search and Comprehension

Regulated copy is dense by necessity, which makes structure the main lever you have left. Short sections, descriptive headings, plain-English summaries above technical detail, and a glossary for the terms you cannot avoid. Structured data helps machines parse the page without you having to soften the clinical language.

POM, OTC and Unbranded: Three Site Types, Three Rule Sets

Most confusion in pharma web design comes from treating "the website" as a single thing. In practice a UK pharmaceutical company usually operates three distinct types of web property, and the rules differ sharply between them.

• Prescription-only medicine (POM) sites. These cannot be promoted to the public at all. In practice this means the branded product content sits behind an HCP gate, and the public-facing route is limited to legitimate non-promotional information. Get this wrong and you are not making a marketing mistake, you are making a regulatory one.
• Over-the-counter and pharmacy medicine sites. These can be advertised to the public, but the advertising must comply with the rules in Part 14 of the Human Medicines Regulations 2012, including mandatory information and a prohibition on misleading claims. The design challenge here is fitting the required information into a layout that still converts.
• Unbranded disease-awareness sites. These educate about a condition without naming a product. They are a legitimate and widely used route to reach patients on POM-treated conditions, but the line between education and disguised promotion is exactly where complaints are made. Keep the product entirely absent, keep the clinical information balanced across treatment options, and document the editorial process.

Deciding which of the three you are building, before wireframes, removes most of the downstream argument. Companies that skip this step end up with one site trying to serve all three purposes, which satisfies none of them and is very difficult to defend.

Life Sciences, Biotech and Research Organisations

Not every organisation in this space markets a medicine. Contract research organisations, biotech firms pre-approval, diagnostics companies, and pharmaceutical research groups have a different problem: they are not advertising to patients at all, they are selling credibility to investors, partners, and recruiters.

That shifts the design priorities substantially. Pipeline and platform pages replace product pages. Publication lists, trial registrations, and named scientific leadership do the work that customer testimonials do elsewhere. Investor relations content needs its own governance, since it carries disclosure obligations that have nothing to do with the MHRA. And recruitment matters far more than it does for a commercial pharma site, because the scarce resource is scientists rather than customers.

The regulatory load is lighter, but the content burden is heavier. A pharmaceutical research website that looks like a generic B2B site will underperform, because the audience is unusually good at detecting imprecision. Specificity is the conversion mechanism: name the modality, name the target, name the phase, cite the paper. Vagueness reads as weakness to this audience in a way it does not elsewhere.

Designing for Patients, Prescribers and Investors

Three audiences, three genuinely different information needs, and one site. This is the core UX problem.

Patients and carers arrive worried and often on a phone. They need plain-English answers, realistic expectations, and an obvious route to the information their clinician will want them to have. Reading age matters: aim for accessible language without being patronising, and put the summary before the detail rather than after it.

Prescribers and pharmacists arrive sceptical and time-poor. They want the data, the references, the dosing, and the safety profile, and they want it in two clicks. Nothing damages credibility faster with this group than making them scroll past patient-facing reassurance to reach the evidence.

Investors and partners want pipeline, milestones, regulatory status, and leadership. They will read your news section chronologically and notice gaps.

The mistake is trying to serve all three from a shared homepage. The better pattern is a clear, early fork, with each path fully self-contained afterwards, and no cross-contamination of tone between them. The same logic applies in other regulated sectors: our guides to medical website design and web design for financial advisers cover the same audience-splitting problem under different rulebooks.

Common UX Problems in Pharma and HCP Portals

Pharmaceutical sites fail their users in a small number of repeatable ways, and almost all of them come from compliance decisions taken without a UX counterweight. These are the issues we find most often when auditing an existing pharma or HCP portal.

• The gate asks for more than it needs. A self-certification interstitial only has to establish that the visitor is a UK healthcare professional. When it is expanded into a full registration form with specialty, GMC number and a password, the drop-off is severe and the extra data is rarely used. Gate first, register later, and only where the content genuinely requires it.
• Prescribing information is buried. It has to be present and prominent, but it is often reduced to a footer link on page 12. Put a persistent, clearly labelled route to prescribing information and safety data on every promotional HCP page.
• Everything is a PDF. Summaries of product characteristics, patient leaflets, dosing guides and slide decks dumped as PDFs are hard to read on a phone, invisible to assistive technology if scanned, and effectively unsearchable. Publish the HTML version first and offer the PDF as the download.
• Site search does not understand clinical vocabulary. Prescribers search by molecule, brand, indication and abbreviation interchangeably. A search index that only matches page titles will return nothing for two of those four, and the user assumes the content does not exist.
• Session timeouts discard work. Security policies on HCP portals often log users out aggressively. If that happens mid-form on an adverse event report or an unfilled sample request, the content is lost and frequently not re-entered.
• Dosing tables break on mobile. A wide clinical table that requires horizontal scrolling on a phone is the single most common accessibility and usability failure on HCP content, and a substantial share of prescriber traffic is mobile.
• The patient route and the HCP route look identical. If both sides share a template and a tone, users lose track of which section they are in, which is a compliance risk as well as a usability one. Signpost the context persistently, not just at the fork.

None of these require loosening a compliance position. They are all cases where the compliant option and the usable option were never properly reconciled, and a competent pharma web design process reconciles them at wireframe stage rather than at launch.

Accessibility Is a Legal Question, Not a Design Preference

There is persistent confusion about which accessibility law applies to whom, so to be precise about it. The Public Sector Bodies (Websites and Mobile Applications) Accessibility Regulations 2018 impose a WCAG-based duty on public sector organisations, which most pharmaceutical companies are not. However, the Equality Act 2010 requires service providers to make reasonable adjustments for disabled people, and that duty does apply to private companies including pharma.

In practice, the sensible target is the same either way: WCAG 2.2 at AA. It is the recognised benchmark, it is what a court or a complainant would reference, and it is what NHS and public sector partners will expect if you ever work with them. Treating it as optional on a site whose users disproportionately have disabilities is difficult to justify commercially, let alone ethically.

Inclusive Web Design for Pharma: Beyond the WCAG Checklist

Accessibility compliance and inclusive design are related but not the same. Compliance asks whether the page passes a standard. Inclusive design asks whether a real person, on a bad day, with the symptoms your product treats, can actually complete the task. In this sector the gap between the two is unusually wide, and it is where the practical work sits.

• Dosing tables and calculators must be usable with a screen reader, which means real table markup with scope attributes and associated labels, not a visual grid of divs that looks tidy and announces nothing.
• Adverse event forms must be completable by someone experiencing an adverse event. Tremor, blurred vision, nausea and cognitive fog are all plausible states for the person filling that form in. Large targets, forgiving validation, no time limits, and the ability to save and resume.
• Patient information leaflets published as scanned PDFs are invisible to assistive technology. Publish accessible HTML as the primary format and keep the PDF as a secondary download.
• Plain-English summaries are an accessibility feature, not a dumbing-down. Cognitive accessibility is part of WCAG, and a summary above the clinical detail serves anxious patients, carers and time-poor clinicians at the same time.
• Do not rely on colour alone to communicate risk or status. Warning states, contraindication flags and severity scales all need a text or shape cue alongside the colour.
• Test with people, not only with scanners. Automated tools catch roughly a third of real issues. A short moderated session with a screen reader user finds the ones that matter. The W3C's introduction to web accessibility is a reasonable grounding for the team before that session happens.

Pharma Web Design or Pharma Web Development: What the Project Actually Needs

Companies searching for pharma web design services frequently need pharma web development, and the distinction is worth being clear about because it determines the budget, the team and the timeline.

Design work covers the visual system, the information architecture, the content model, and the compliance-aware component library. It is where the audience-splitting and the regulatory constraints get resolved on paper. Development work covers the parts that carry ongoing risk once the site is live.

A useful test: if your problem is that the site looks dated and does not explain the science well, it is a design project. If your problem is that updating a claim takes six weeks and three email chains, or that nobody can prove who approved what, it is a development and workflow project. Most pharmaceutical websites that frustrate their owners are failing on the second, and a redesign will not fix it.

What Pharma Web Development Actually Covers

The engineering scope on a regulated build is wider than on a corporate site of the same page count, and the difference is almost entirely in governance rather than in visual complexity.

• Approval workflow in the CMS. Draft, medical review, regulatory review, approval, publication, expiry. Each state recorded with a user, a timestamp and a version. If this runs over email instead, you have no audit trail when you need one.
• A referenced content model. Claims are structured objects with a reference, an approver and a review date attached, not free text in a WYSIWYG field. That is what makes an annual re-approval cycle tractable instead of a manual page-by-page sweep.
• HCP gating logic. Server-side enforcement, a sensible cookie duration, correct handling of deep links from email and search, and a gate that does not accidentally block your own crawler or analytics.
• Adverse event capture and routing. Validated form handling, encryption, a defined internal notification path with a response time, and a clear onward route to the MHRA Yellow Card scheme.
• Multi-market content governance. Where a product is approved in several markets, the site has to serve market-specific labelling without leaking one market's approved claims into another.
• Integrations. Reference and asset management systems, CRM, consent management, and whatever holds the approved claim library. These are usually the long pole in the schedule.
• Content expiry and review automation. Approvals lapse. The system should surface that before a reviewer does, ideally as a dashboard rather than a calendar reminder.

We handle both sides through web design and WordPress web development, and on regulated projects the workflow build is usually the larger half of the engagement.

Choosing a Pharma Web Design Agency in the UK

Most agencies will say yes to a pharmaceutical project. Fewer have built one that survived a code review. These are the questions that separate the two, and they are worth asking before the pitch rather than after the contract.

1. Ask how they handle claim referencing in the CMS. If the answer is "the client adds the reference in the text", they have not built a regulated site before.
2. Ask what happens when an approval expires. A good answer describes a system behaviour. A weak answer describes a person remembering.
3. Ask who signs off accessibility, and against what. "WCAG 2.2 AA, tested with a screen reader and documented" is the answer you want. "It is responsive" is not.
4. Ask how the HCP gate is enforced. Client-side only is a red flag, because the content is still fetchable.
5. Ask about the handover. A regulated site your team cannot update without the agency is a compliance risk, because urgent safety updates do not wait for a support queue.
6. Ask what they maintain after launch. Security patching, dependency updates and accessibility regression testing on a regulated site are continuing obligations, not an optional retainer.

Sector-specific experience helps, but it is not the only signal. An agency with a strong track record in another heavily regulated sector, and an honest process for working with your medical and regulatory colleagues, will usually outperform one that has pharma logos on the wall and a purely visual process behind them.

A Practical Build and Maintenance Checklist

1. Confirm which site type you are building: POM, OTC, unbranded awareness, or corporate and research.
2. Map audiences to site sections and define the gating rule for each before wireframing.
3. Build a content model where every claim has a reference field, an approver, and a review date.
4. Agree the sign-off workflow with medical and regulatory colleagues, and build it into the CMS rather than running it over email.
5. Set WCAG 2.2 AA as the acceptance criterion and test with a screen reader, not only an automated scanner.
6. Implement adverse event reporting with a clear route to the MHRA Yellow Card scheme and an internal notification path with a defined response time.
7. Run a UK GDPR review covering special category data, retention, and your data protection impact assessment.
8. Schedule content review cycles by expiry date, so approvals lapse visibly rather than silently.
9. Structure the site for search: descriptive headings, clean URLs, and schema markup that does not overstate claims. Our SEO team works within the same constraints rather than around them.
10. Plan the maintenance budget alongside the build budget. Regulated sites decay faster because their content has a shelf life.

If the promotional side is also in scope, our companion guide to digital marketing for pharmaceutical companies covers the channel-level rules, and dental web design covers a lighter-touch regulated healthcare build if that is closer to your situation.

Frequently Asked Questions